or
forgot password

    • cancer clinical trials in bridgewater, NJ

    • Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer
    Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807
    Breast Neoplasms
    Docetaxel in Breast Cancer
    Sanofi-Aventis
    Bridgewater, New Jersey 08807
    Breast Cancer
    TRACE: Tirapazamine-Radiation And Cisplatin Evaluation
    Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807
    Head and Neck Squamous Cell Carcinoma
    Adjuvant Leuprolide With or Without Docetaxel in High Risk Prostate Cancer After Radical Prostatectomy
    Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807
    Prostatic Neoplasms
    Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma
    Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807
    Pulmonary Diseases, Neoplasms, Lung
    TEACO: Taxotere, Eloxatin, Avastin in Cancer of the Ovary
    Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807
    Ovarian Cancer
    Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.
    Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807
    Metastases, Colorectal Neoplasms, Colorectal Carcinoma
    Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer
    Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807
    Neoplasms, Cancer of the Ovary
    Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites
    Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807
    Ovarian Neoplasms, Ascites
    Combination Study of a New Taxane and Capecitabine in Patients With Metastatic Breast Cancer
    Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807
    Breast Cancer, Cancer
    Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC)
    Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807
    Non-Small Cell Lung Cancer
    Pilot Study of Docetaxel & Bevacizumab +/- Trastuzumab in First-Line Treatment of Patients With Metastatic Breast Cancer
    Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807
    Breast Cancer
    Docetaxel and Oxaliplatin in Gastric Cancer
    Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807
    Stomach Neoplasms
    AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites
    Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807
    Ovarian Neoplasms
    TREE-2: Three Regimens of Eloxatin in Advanced Colorectal Cancer
    Sanofi-Aventis
    Bridgewater, New Jersey 08807
    Colorectal Cancer
    Taxotere (Docetaxel) in 1st Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
    Sanofi-Aventis US
    Bridgewater, New Jersey 08807
    Head and Neck Neoplasms, Neoplasm Recurrence, Local, Neoplasm Metastasis
    XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer
    Sanofi-Aventis US
    Bridgewater, New Jersey 08807
    Neoplasms, Prostatic Neoplasms
    Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer
    Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807
    Prostatic Neoplasms, Neoplasm Metastasis
    A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
    Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807
    Carcinoma, Non Small Cell Lung
    Phase I Dose Finding Study of SSR97225 Given in Patients With Refractory Cancer
    Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807
    Neoplasms
    Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's Lymphoma
    Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807
    Lymphoma, Non-Hodgkin
    Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer
    Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807
    Pancreatic Neoplasm
    S-1 Versus 5-FU Bolus in Metastatic Pancreatic Cancer Patients Previously Treated With Gemcitabine-Based Regimen
    Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807
    Pancreatic Neoplasm, Neoplasm Metastasis
    Fasturtec TLS Treatment / Prophylysis
    Sanofi-Aventis
    Bridgewater, New Jersey 08807
    Tumor Lysis Syndrome
    Docetaxel in Node Positive Adjuvant Breast Cancer
    Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807
    Breast Cancer
    Trial of Weekly Taxotere and Irinotecan (CPT-11) in Patients With Advanced Non-small Cell Lung Cancer
    Sanofi-Aventis US
    Bridgewater, New Jersey 08807
    Carcinoma, Non-Small-Cell Lung
    A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer Patients
    Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807
    Cancer
    Observational Registry of Treatment Patterns in Castrate-resistant Prostate Cancer (CRPC) Patients
    Sanofi-Aventis Administrative Office
    Bridgewater, New Jersey 08807
    Prostatic Neoplasms